Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a ...
In this video interview, Kimberly Tableman, founder & CEO, ESPERO, highlights how data standards are empowering the use of ...
In the pivotal trial, patients treated with Omvoh experienced significant improvements in clinical remission and endoscopic ...
An updated long-term analysis of the Phase III KATHERINE trial confirms that adjuvant treatment with Kadcyla (trastuzumab ...
In this video interview, Kimberly Tableman, founder & CEO, ESPERO, discusses historical challenges with long protocol ...
In 2025, sponsors will prioritize contract research organizations (CROs) offering complete and continuous data transparency ...
Pilot trial shows that a user-friendly electronic patient-reported outcome (ePRO) monitoring system significantly improves ...
In this video interview, Kimberly Tableman, founder & CEO, ESPERO, talks protocol submission formats and how data interoperability can support artificial intelligence.
Positive efficacy and safety findings from the TROPION-Lung05 (NCT04484142) and TROPION-Lung01 (NCT04656652) clinical trials led the FDA to award Priority Review designation to a Biologics License ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback